You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

LOTRISONE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LOTRISONE?
  • What are the global sales for LOTRISONE?
  • What is Average Wholesale Price for LOTRISONE?
Summary for LOTRISONE
US Patents:0
Applicants:2
NDAs:2
Raw Ingredient (Bulk) Api Vendors: 72
Clinical Trials: 1
Drug Prices: Drug price information for LOTRISONE
What excipients (inactive ingredients) are in LOTRISONE?LOTRISONE excipients list
DailyMed Link:LOTRISONE at DailyMed
Drug patent expirations by year for LOTRISONE
Drug Prices for LOTRISONE

See drug prices for LOTRISONE

Drug Sales Revenue Trends for LOTRISONE

See drug sales revenues for LOTRISONE

Recent Clinical Trials for LOTRISONE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Jilin UniversityPhase 2

See all LOTRISONE clinical trials

US Patents and Regulatory Information for LOTRISONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon LOTRISONE betamethasone dipropionate; clotrimazole CREAM;TOPICAL 018827-001 Jul 10, 1984 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Merck Sharp Dohme LOTRISONE betamethasone dipropionate; clotrimazole LOTION;TOPICAL 020010-001 Dec 8, 2000 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LOTRISONE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Organon LOTRISONE betamethasone dipropionate; clotrimazole CREAM;TOPICAL 018827-001 Jul 10, 1984 ⤷  Subscribe ⤷  Subscribe
Organon LOTRISONE betamethasone dipropionate; clotrimazole CREAM;TOPICAL 018827-001 Jul 10, 1984 ⤷  Subscribe ⤷  Subscribe
Organon LOTRISONE betamethasone dipropionate; clotrimazole CREAM;TOPICAL 018827-001 Jul 10, 1984 ⤷  Subscribe ⤷  Subscribe
Organon LOTRISONE betamethasone dipropionate; clotrimazole CREAM;TOPICAL 018827-001 Jul 10, 1984 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

LOTRISONE Market Analysis and Financial Projection Experimental

LOTRISONE Market Dynamics and Financial Trajectory

Overview of LOTRISONE

LOTRISONE, a combination of clotrimazole and betamethasone dipropionate, is a widely prescribed topical antifungal and corticosteroid medication. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of various cutaneous fungal infections, including tinea pedis, tinea cruris, and tinea corporis[3].

Market Size and Growth

The market for antifungal drugs, including LOTRISONE, is projected to grow significantly. The clotrimazole market, a segment of the broader antifungal market, is estimated to reach $4.2 billion by 2030, growing at a CAGR of 6.2% during the forecast period 2024-2030[1].

Key Market Drivers

Increasing Prevalence of Fungal Infections

The rising incidence of fungal infections such as athlete's foot, vaginitis, and other dermatophytoses is a major driver for the growth of the LOTRISONE market. This increase is attributed to various factors, including climate change, urbanization, and improved diagnostic techniques[1].

Growing Application in Disease Treatment

LOTTRISONE's versatility in treating a range of fungal infections, along with its combination of antifungal and corticosteroid properties, makes it a preferred choice for many healthcare providers. This broader application contributes to its market growth[1].

Consumer Awareness and Preference for OTC Treatments

Consumers increasingly prefer over-the-counter (OTC) antifungal treatments for their convenience and ease of access. LOTRISONE, being available in various forms and often prescribed as an OTC medication, benefits from this trend[4].

Market Challenges

Cost-Effectiveness and Side Effects

LOTTRISONE is more expensive than clotrimazole alone and has been associated with several steroid-related side effects, such as striae distensae, hirsutism, and growth retardation, particularly in children. These factors can limit its use and impact its cost-effectiveness[3].

Regulatory and Quality Control Issues

The market faces challenges related to product recalls and counterfeit products, which can erode consumer trust. Regulatory bodies like the FDA and EMA play a crucial role in ensuring product safety and efficacy, but stringent quality control measures are necessary to maintain market integrity[4].

Regional Dynamics

North America and Europe

These regions dominate the market due to high consumer awareness and advanced healthcare infrastructure. Companies like Bayer, with its top brands Tinactin, Lotrimin Ultra, and Lotrimin AF, hold significant market shares in these regions[4].

Asia Pacific

The Asia Pacific region presents significant growth potential due to a large target population and increasing healthcare investments. Understanding regional trends and consumer behavior is crucial for companies to tailor their strategies effectively in this market[4].

Financial Performance

Revenue and Market Share

LOTTRISONE, as part of the broader clotrimazole market, contributes to the revenue of major pharmaceutical companies. For instance, Bayer's dominance in the antifungal market, with brands like Lotrimin AF holding an 11% market share, indicates the financial significance of LOTTRISONE and similar products[4].

Cost Analysis

LOTTRISONE is considerably more expensive than clotrimazole alone and accounts for a substantial portion of topical antifungal expenditures. However, its combination therapy offers a unique value proposition that justifies the higher cost for many consumers and healthcare providers[3].

Competitive Landscape

Key Players

The market is dominated by key players such as Bayer, Novartis AG, and other pharmaceutical companies. These companies engage in strategic initiatives like new product launches, mergers, and public awareness campaigns to maintain their market positions[1][4].

Strategic Initiatives

Companies are focusing on innovation, quality control, and regulatory compliance to address market challenges. For example, the emphasis on natural remedies and the development of new, safer antifungal treatments are strategic moves to capture a larger market share[4].

Impact of COVID-19 and Other Crises

Market Resilience

The COVID-19 pandemic and other global crises have had varying impacts on the pharmaceutical industry. However, the essential nature of antifungal medications like LOTRISONE has helped the market remain relatively resilient. Online pharmacies have seen significant growth, further supporting the market's stability[1].

Key Takeaways

  • The LOTRISONE market is driven by the increasing prevalence of fungal infections and consumer preference for OTC treatments.
  • Despite being more expensive and associated with side effects, LOTRISONE's unique combination therapy maintains its market relevance.
  • Regional dynamics, particularly in North America, Europe, and the Asia Pacific, play a crucial role in shaping the market.
  • Major pharmaceutical companies are key players, with strategies focused on innovation and regulatory compliance.
  • The market is expected to grow at a CAGR of 6.2% during the forecast period 2024-2030.

FAQs

Q: What is LOTRISONE used for?

LOTTRISONE is used for the treatment of various cutaneous fungal infections, including tinea pedis, tinea cruris, and tinea corporis.

Q: Why is LOTRISONE more expensive than clotrimazole alone?

LOTTRISONE is a combination of clotrimazole and betamethasone dipropionate, which makes it more expensive due to the added corticosteroid component.

Q: What are the potential side effects of LOTRISONE?

LOTTRISONE can cause steroid-related side effects such as striae distensae, hirsutism, and growth retardation, particularly in children.

Q: Which regions dominate the LOTRISONE market?

North America and Europe dominate the market due to high consumer awareness and advanced healthcare infrastructure.

Q: What is the projected growth rate of the clotrimazole market, which includes LOTRISONE?

The clotrimazole market is projected to grow at a CAGR of 6.2% during the forecast period 2024-2030.

Sources:

  1. IndustryARC, Clotrimazole Market - Forecast(2017-2025) Research Report.
  2. NJ.gov, THE STATE OF ALABAMA - NJ.gov.
  3. PubMed, Clotrimazole/betamethasone diproprionate: a review of costs and ...
  4. Grand View Research, Brand Analysis Of Key 20 Antifungal Drugs For Athlete's Foot.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.